Department of Neurology, Weill Cornell Medical College, New York, NY, USA.
Mult Scler. 2018 Apr;24(4):540-542. doi: 10.1177/1352458517699876. Epub 2017 Mar 13.
Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported.
We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab.
In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.
阿仑单抗是一种已被批准用于治疗复发缓解型多发性硬化症（RRMS）的单克隆抗体。尽管在输注阿仑单抗后已经报道了免疫性血小板减少症（ITP）是继发的自身免疫现象，但在输注期间发生即时性血小板减少症尚未见报道。
我们报告了在首个阿仑单抗疗程期间出现短暂、可逆、自限性急性发作的血小板减少症。
共有 22 例患者中的 3 例患者在最初的 5 天阿仑单抗疗程中出现轻度自限性瘀斑，并伴有血小板计数从基线水平下降。通过病历回顾，所有接受阿仑单抗治疗的 22 例患者均出现了即刻且通常无症状的血小板计数下降，在输注后 2 个月内恢复正常。
